EP Patent

EP2923706A1 — Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia

Assigned to Synergy Pharmaceuticals Inc · Expires 2015-09-30 · 11y expired

What this patent protects

This invention also provides a method to prevent, control and treat lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a co…

USPTO Abstract

This invention also provides a method to prevent, control and treat lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

Drugs covered by this patent

Patent Metadata

Patent number
EP2923706A1
Jurisdiction
EP
Classification
—
Expires
2015-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Synergy Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.